Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

References

• GugliottaGCastagnettiFApolinariMFirst-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategiesDrugs201474662764324711014
   PubMed Web of Science ®Google Scholar
• JabbourEKantarjianHChronic myeloid leukemia: 2014 update on diagnosis, monitoring, and managementAm J Hematol201489554755624729196
   PubMed Web of Science ®Google Scholar
• ChenRChenBThe role of dasatinib in the management of chronic myeloid leukemiaDrug Des Devel Ther20159773779
   PubMed Web of Science ®Google Scholar
• BixbyDTalpazMSeeking the causes and solutions to imatinib-resistance in chronic myeloid leukemiaLeukemia201125172221102425
   PubMed Web of Science ®Google Scholar
• BaccaraniMDeiningerMWRostiGEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Blood2013122687288423803709
   PubMed Web of Science ®Google Scholar
• BakerSJReddyEPTargeted inhibition of kinases in cancer therapyMt Sinai J Med201077657358621105121
   PubMedGoogle Scholar
• SchenoneSBrulloCMusumeciFBottaMNovel dual Src/Abl inhibitors for hematologic and solid malignanciesExpert Opin Investig Drugs2010198931945
   PubMed Web of Science ®Google Scholar
• HaoualaAWidmerNDuchosalMAMontemurroMBuclinTDecosterdLADrug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinibBlood20111178e75e8720810928
   PubMed Web of Science ®Google Scholar
• LiuFLangLWJiangJLuHJWangJMWangSCSynthesis and biopharmaceutical studies of JLTN as potential dasatinib prodrugChem Pharm Bull (Tokyo)201361887788123676628
   PubMed Web of Science ®Google Scholar
• CondorelliFGenazzaniAADasatinib: is it all in the dose?BioDrugs201024315716320222756
   PubMed Web of Science ®Google Scholar
• McFarlandKLWetzsteinGAChronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitorsCancer Control200916213214019337199
   PubMed Web of Science ®Google Scholar
• SteinBSmithBDTreatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinibClin Ther201032580482020685492
   PubMed Web of Science ®Google Scholar
• JabbourEDeiningerMHochhausAManagement of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemiaLeukemia201125220121020861918
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkChronic Myeloid Leukemia (Version 1.2016) Available from: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdfAccessed February 2, 2016
   Google Scholar
• ShahNPKimDWKantarjianHPotent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibHaematologica201095223224020139391
   PubMed Web of Science ®Google Scholar
• ReaDVellengaEJunghanssCSix-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia receiving dasatinibHaematologica201297Suppl 1199
   Google Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2010362242260227020525995
   PubMed Web of Science ®Google Scholar
• KantarjianHMShahNPCortesJEDasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow up from a randomized phase 3 trial (DASISION)Blood201211951123112922160483
   PubMed Web of Science ®Google Scholar
• RadichJPKopeckyKJAppelbaumFRA randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic phase chronic myeloid leukemiaBlood2012120193898390522915637
   PubMed Web of Science ®Google Scholar
• Hjorth-HansenHStenkeLSöderlundSNordic CML Study GroupDasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)Eur J Haematol201594324325025082346
   PubMed Web of Science ®Google Scholar
• LarsonRAIs there a best TKI for chronic phase CML?Blood2015126212370237526585806
   PubMed Web of Science ®Google Scholar
• KeskinDEskazanAEThe treatment of chronic myeloid leukaemia (CML) in the era of tyrosine kinase inhibitors – what is new in the battle of CML?Eur Oncol Haematol20151113031
   Google Scholar
• CarneiroBAKaplanJBGilesFJTyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse eventsExpert Rev Hematol20158445747925938861
   PubMed Web of Science ®Google Scholar
• GugliottaGCastagnettiFFogliMImpact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitorsExpert Rev Hematol20136556357424083631
   PubMed Web of Science ®Google Scholar
• SoveriniSHochhausANicoliniFEBCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetBlood201111851208121521562040
   PubMed Web of Science ®Google Scholar
• EskazanAESoysalTErbilginYOzbekUFerhanogluBChronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?Leuk Res2011359e145e14621605905
   PubMed Web of Science ®Google Scholar
• EşkazanAESoysalTDasatinib may override F317L BCR-ABL kinase domain mutation in patients with chronic myeloid leukemiaTurk J Haematol201330221121324385789
   PubMed Web of Science ®Google Scholar
• TiribelliMLatagliataRLucianoLImpact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemiaAnn Hematol201392217918323053188
   PubMed Web of Science ®Google Scholar
• Pinilla-IbarzJCortesJMauroMJIntolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implicationsCancer2011117468869720922786
   PubMed Web of Science ®Google Scholar
• HochhausABaccaraniMDeiningerMDasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibLeukemia20082261200120618401416
   PubMed Web of Science ®Google Scholar
• KantarjianHPasquiniRLévyVDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)Cancer2009115184136414719536906
   PubMed Web of Science ®Google Scholar
• ShahNPKantarjianHMKimDWIntermittant target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaJ Clin Oncol200826193204321218541900
   PubMed Web of Science ®Google Scholar
• ValentPHadzijusufovicESchernthanerGHWolfDReaDle CoutrePVascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitorsBlood2015125690190625525119
   PubMed Web of Science ®Google Scholar
• O’HareTWaltersDKStoffregenEPIn vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutantsCancer Res200565114500450515930265
   PubMed Web of Science ®Google Scholar
• Quintas-CardamaAKantarjianHO’BrienSPleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failureJ Clin Oncol200725253908391417761974
   PubMed Web of Science ®Google Scholar
• PorkkaKKhouryHJPaquetteRLMatloubYSinhaRCortesJEDasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusionCancer2010116237738619924787
   PubMed Web of Science ®Google Scholar
• EskazanAEEyiceDKurtEAChronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusionLeuk Res201438778178724832371
   PubMed Web of Science ®Google Scholar
• EskazanAESoysalTOngorenSGulturkEFerhanogluBAydinYPleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapyHaematologica2011963e1521357709
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAKantarjianHCortesJNilotinib-associated vascular eventsClin Lymphoma Myeloma Leuk201212533734022633167
   PubMed Web of Science ®Google Scholar
• AichbergerKJHerndlhoferSSchernthanerGHProgressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CMLAm J Hematol201186753353921538470
   PubMed Web of Science ®Google Scholar
• Gora-TyborJMedrasECalbeckaMReal-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatmentLeuk Lymphoma20155682309231425563556
   PubMed Web of Science ®Google Scholar
• DouxfilsJHaguetHMullierFAssociation between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysisJAMA Oncol Epub24201610.1001/jamaoncol.2015.5932
   Web of Science ®Google Scholar
• DahlénTEdgrenGLambeMSwedish CML Group and the Swedish CML Register GroupCardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based Cohort studyAnn Intern Med Epub614201610.7326/M15-2306
   PubMed Web of Science ®Google Scholar
• ShahNPWallisNFarberHWClinical features of pulmonary arterial hypertension in patients receiving dasatinibAm J Hematol201590111060106426284693
   PubMed Web of Science ®Google Scholar
• Ozgur YurttasNSadriSKeskinDReal-life data and a single center experience on dasatinib-induced pulmonary arterial hypertension in patients with Philadelphia chromosome-positive leukemiasBlood2015126234037
   Web of Science ®Google Scholar
• PeacockAJMurphyNFMcMurrayJJCaballeroLStewartSAn epidemiological study of pulmonary arterial hypertensionEur Respir J200730110410917360728
   PubMed Web of Science ®Google Scholar
• GuignabertCMontaniDKey roles of Src family tyrosine kinases in the integrity of the pulmonary vascular bedEur Respir J20134113423277514
   PubMed Web of Science ®Google Scholar
• KimDHKamel-ReidSChangHNatural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemiaHaematologica200994113513919066329
   PubMed Web of Science ®Google Scholar
• MustjokiSEkblomMArstilaTPClonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapyLeukemia20092381398140519295545
   PubMed Web of Science ®Google Scholar
• NagataYOhashiKFukudaSKamataNAkiyamaHSakamakiHClinical features of dasatinib-induced large granular lymphocytosis and pleural effusionInt J Hematol201091579980720405252
   PubMed Web of Science ®Google Scholar
• PaydasSDasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?Crit Rev Oncol Hematol201489224224724210599
   PubMed Web of Science ®Google Scholar
• QiuZYXuWLiJYLarge granular lymphocytosis during dasatinib therapyCancer Biol Ther201415324725524352048
   PubMed Web of Science ®Google Scholar
• TanakaHNakashimaSUsudaMRapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patientsInt J Hematol201296330831922767140
   PubMed Web of Science ®Google Scholar
• KreutzmanAJaatinenTGrecoDKiller-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemiaExp Hematol20124011906913.e122842045
   PubMed Web of Science ®Google Scholar
• RouxCNicoliniFEReaDReversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phaseBlood2013122173082308424159167
   PubMed Web of Science ®Google Scholar
• OzawaMGEwaltMDGratzingerDDasatinib-related follicular hyperplasia: an underrecognized entity with characteristic morphologyAm J Surg Pathol201539101363136926360368
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAKantarjianHRavandiFBleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapyCancer2009115112482249019280591
   PubMed Web of Science ®Google Scholar
• Quintás-CardamaAHanXKantarjianHCortesJTyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemiaBlood2009114226126319414863
   PubMed Web of Science ®Google Scholar
• EskazanAEHatemiİÖngören AydınSArMCSoysalTAcute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapyTurk J Gastroenterol201425Suppl 1233
   PubMedGoogle Scholar
• ErkutMErkutNErsozSArslanMSonmezMA case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib useActa Haematol2010123420520620375493
   PubMed Web of Science ®Google Scholar